Free tool
FAERS Monitor: Avapro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020757 or its brand name (Avapro, Irbesartan). Reports on generic versions are filed under their own applications.
Reports
45,095
Serious
35,266
78% of reports
Hospitalization
19,285
Death reported
3,341
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,569
- nausea2,514
- diarrhoea2,369
- drug ineffective2,237
- acute kidney injury2,187
- dizziness2,059
- dyspnoea2,058
- fall2,038
- headache1,966
- off label use1,773
- asthenia1,767
- malaise1,700
- vomiting1,595
- pain1,591
- blood pressure increased1,537
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 834 |
| 2005 | 1,000 |
| 2006 | 1,052 |
| 2007 | 1,194 |
| 2008 | 1,227 |
| 2009 | 1,312 |
| 2010 | 1,329 |
| 2011 | 1,484 |
| 2012 | 1,514 |
| 2013 | 1,209 |
| 2014 | 1,486 |
| 2015 | 1,794 |
| 2016 | 1,991 |
| 2017 | 1,947 |
| 2018 | 2,715 |
| 2019 | 3,633 |
| 2020 | 3,369 |
| 2021 | 2,778 |
| 2022 | 2,931 |
| 2023 | 2,893 |
| 2024 | 2,637 |
| 2025 | 2,763 |
| 2026 | 2,001 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,009,064 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 2,187 | 6.7 | 6.5 | 10,626 |
| blood pressure increasedSignal | 1,537 | 4.7 | 4.5 | 4,499 |
| fallSignal | 2,038 | 2.9 | 2.7 | 2,501 |
| astheniaSignal | 1,767 | 2.2 | 2.1 | 1,167 |
| dizziness | 2,059 | 1.9 | 1.8 | 939 |
| malaise | 1,700 | 1.8 | 1.7 | 627 |
| diarrhoea | 2,369 | 1.7 | 1.6 | 724 |
| dyspnoea | 2,058 | 1.7 | 1.6 | 604 |
| vomiting | 1,595 | 1.6 | 1.5 | 350 |
| fatigue | 2,569 | 1.5 | 1.5 | 504 |
| nausea | 2,514 | 1.5 | 1.4 | 409 |
| headache | 1,966 | 1.5 | 1.4 | 297 |
| pain | 1,591 | 1.2 | 1.2 | 59 |
| off label use | 1,773 | 0.9 | 0.9 | 6 |
| drug ineffective | 2,237 | 0.8 | 0.8 | 131 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.